J
Joel M. Reid
Researcher at Mayo Clinic
Publications - 274
Citations - 11448
Joel M. Reid is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pharmacokinetics & Medicine. The author has an hindex of 50, co-authored 248 publications receiving 10094 citations. Previous affiliations of Joel M. Reid include Oregon Health & Science University & Upjohn.
Papers
More filters
Journal ArticleDOI
Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group
Steven G. DuBois,Mark Krailo,Julia Glade-Bender,Allen Buxton,Nadia N. Laack,R. Lor Randall,Helen X. Chen,Nita L. Seibel,Matthew Boron,Stephanie A. Terezakis,Christine E. Hill-Kayser,Andrea Hayes,Joel M. Reid,Lisa A. Teot,Dinesh Rakheja,Richard B. Womer,Carola A.S. Arndt,Stephen L. Lessnick,Brian D. Crompton,E. Anders Kolb,Heike E. Daldrup-Link,Eric P. Eutsler,Damon R. Reed,Katherine A. Janeway,Richard Gorlick +24 more
TL;DR: In this paper , Ganitumab was added to interval-compressed chemotherapy in patients with newly diagnosed metastatic Ewing sarcoma, with outcomes similar to prior trials without IGF-1R inhibition or interval compression.
Journal ArticleDOI
Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: A Children's Oncology Group Phase I Consortium study
Lars M. Wagner,John P. Perentesis,Joel M. Reid,Matthew M. Ames,Stephanie L. Safgren,Marvin D. Nelson,Ashish M. Ingle,Susan M. Blaney,Peter C. Adamson +8 more
TL;DR: Activity on this and prior studies suggests a potential role for VOIT in sarcoma patients, and the dx5x1 schedule of VOIT was well tolerated, with SN-38 exposures similar to those achieved with intravenous IRN.
Journal ArticleDOI
Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas.
Patrick Y. Wen,Vinay K. Puduvalli,John G. Kuhn,Joel M. Reid,K. Lamborn,T. Cloughesy,Susan M. Chang,J. Drappatz,W. K. A. Yung,Mark R. Gilbert,H. I. Robins,Frank S. Lieberman,Andrew B. Lassman,Renee M. McGovern,Serena Desideri,Xiaobu Ye,Matthew M. Ames,Igor Espinoza-Delgado,Stuart A. Grossman,M. Prados +19 more
TL;DR: Vorinostat is well tolerated in combination with TMZ and led to an ABTC and NCCTG phase II trial of vor inostat with RT and TMZ in newly-diagnosed GBM.
Journal ArticleDOI
Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children’s Oncology Group phase I consortium study
Sabine Mueller,Tabitha Cooney,Xiaoyong Yang,Sharmistha Pal,Ralph P. Ermoian,Amar Gajjar,Xiaowei Liu,Komal Prem,Charles G. Minard,Joel M. Reid,Marvin D. Nelson,Daphne A. Haas-Kogan,Elizabeth Fox,Brenda J. Weigel +13 more
TL;DR: Adavosertib in combination with CRT is well tolerated in children with newly diagnosed DIPG, however, compared to historical controls, did not improve OS and can inform future trial design in childrenWith high-risk cancer.
Journal ArticleDOI
Characterization of Batracylin-induced Renal and Bladder Toxicity in Rats
Myrtle Davis,Deborah I. Bunin,Steven Samuelsson,Kenneth P. Altera,Robert J. Kinders,Scott M. Lawrence,Jiuping Ji,Matthew M. Ames,Sarah A. Buhrow,Chad A. Walden,Joel M. Reid,Linda L. Rausch,Toufan Parman +12 more
TL;DR: It is suggested that batracylin results in DNA damage-based mechanisms of toxicity and not an acrolein-based mechanism of toxicity as occurs after ifosfamide or cyclophosphamide administration.